Big Moving Stock keep track of the biggest moving stocks in the market.
The Hot Industries
Business Services 2
Aerospace/Defense Products & Services 2
The Hot Sectors
Basic Materials 4
Consumer Goods 3
ARIA Ariad Pharmaceuticals Inc.
ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. The company focuses on commercializing Iclusig (ponatinib), a cancer medicine; and developing additional molecularly targeted therapies to treat patients with blood cancers and solid tumors. Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States for the treatment of adult patients with chronic, accelerated, or blast phase chronic myeloid leukemia, who are resistant or intolerant to prior TKI therapy, as well as for the treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, who are resistant or intolerant to prior TKI therapy. Its product pipeline consists of AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase, which is being studied in a phase I/II clinical trial in patients with advanced solid tumors comprising non-small cell lung cancer; Ridaforolimus, an investigational mTOR inhibitor, which is being studied in multiple clinical trials in patients with various types of cancers; and AP1903, a small-molecule dimerizer drug. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus, for use in cancer; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.
Stock Market Today: Biotech, Social Media Stocks Slide Following Yellen's Remarks15 Jul 2014, 8:06 amNEW YORK (TheStreet) -- Major U.S. stock markets tumbled Tuesday following Federal Reserve Chair Janet Yellen's prepared remarks to the Senate Banking Committee that some sectors of the markets, notably biotech and social media, appear overvalued. The iShares Nasdaq Biotechnology Index ETF slid 2.6% on the remarks, as MannKind dropped 1.7%, Geron moved 5% lower, and Ariad Pharmaceuticals was ...
Why A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock - Tale of the Tape7 Jul 2014, 7:58 amWhy A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock - Tale of the Tape
Why A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock7 Jul 2014, 5:42 amWhy A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock
Alcobra (ADHD) Jumps: Stock Adds 5.9% in Session3 Jul 2014, 6:16 amAlcobra (ADHD) was a big mover last session, with shares rising nearly 6% on the day.
Zogenix, Inc. (ZGNX) Soars: Stock Adds 18.6% in Session3 Jul 2014, 5:03 amZogenix, Inc. (ZGNX) was a big mover last session, as its shares rose nearly 19% on the day.
Auxilium Pharmaceuticals (AUXL) Crumbles: Stock Falls by 5.6%1 Jul 2014, 4:54 amAuxilium Pharmaceuticals has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Heron Therapeutics (HRTX) in Focus: Stock Falls 8.9% in Session26 Jun 2014, 5:00 amHeron Therapeutics saw a big move last session on pretty good volume with far more shares changing hands than in a normal session; shares fell almost 9% on the day.
ARIAD Announces Proposed $175 Million Offering of Convertible Senior Notes Due 201924 Jun 2014, 5:21 pmCAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced its intention to offer, subject to market and other conditions, $175 million aggregate principal amount of convertible senior notes due 2019 (the “Notes”) in a private placement. The Notes will be offered by the initial purchasers only to qualified institutional buyers pursuant to Rule 144A under the ...
Ohr Pharmaceutical (OHRP) Soars: Stock Adds 16.9% in Session24 Jun 2014, 4:59 amOhr Pharmaceutical, Inc. (OHRP) was a big mover last session, as the company saw its shares rise by almost 17% on the day.
ARIAD Announces Pricing of $200 Million Offering of 3.625% Convertible Senior Notes Due 201923 Jun 2014, 2:57 pmCAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the pricing of $200 million aggregate principal amount of its 3.625% convertible senior notes due 2019 (the “Notes”) in a private placement. The Notes will be offered by the initial purchasers only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the ...